Camrelizumab, formerly known as SHR-1210, represents a significant advancement in tumor immune therapy , functioning as a monoclonal that inhibits the programmed death-1 receptor. This checkpoint protein, expressed on immune cells , normally restrains anti-tumor immune responses, allowing cancerous growths to evade recognition by the body’s defe… Read More